Shanghai Qingpu Central Hospital Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04642378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai Qingpu Central Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

tislelizumab (1 trial)

Drugs in Other Trials (1)

insulin human (humulin) (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2